GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » PS Ratio

Sunesis Pharmaceuticals (FRA:RYIS) PS Ratio : 135.63 (As of May. 12, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sunesis Pharmaceuticals's share price is €16.275016. Sunesis Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was €0.12. Hence, Sunesis Pharmaceuticals's PS Ratio for today is 135.63.

The historical rank and industry rank for Sunesis Pharmaceuticals's PS Ratio or its related term are showing as below:

FRA:RYIS's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.095
* Ranked among companies with meaningful PS Ratio only.

Sunesis Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2020 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was €0.12.

Back to Basics: PS Ratio


Sunesis Pharmaceuticals PS Ratio Historical Data

The historical data trend for Sunesis Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals PS Ratio Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.38 135.09 62.44 14.19 232.17

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.19 21.11 13.40 6.36 232.17

Competitive Comparison of Sunesis Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Sunesis Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's PS Ratio falls into.



Sunesis Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Sunesis Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=16.275016/0.12
=135.63

Sunesis Pharmaceuticals's Share Price of today is €16.275016.
Sunesis Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.12.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Sunesis Pharmaceuticals  (FRA:RYIS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Sunesis Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines